Atlas Trials

Chong Kun Dang Pharmaceutical

299 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Chong Kun Dang Pharmaceutical

RecordFirmDate
Study to Evaluate the Efficacy and Safety of CKD-352 (NCT04548427)Chong Kun Dang Pharmaceutical2020-09-22
Evaluation of the Safety and Tolerability of CKD-508 in Healthy Subjects (NCT04488900)Chong Kun Dang Pharmaceutical2020-07-06
Efficacy and Safety of Everolimus Versus Mycophenolate Mofetil in Liver Transplant Recipients. (NCT04471441)Chong Kun Dang Pharmaceutical2020-06-30
A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D759 and D150 (CKD-393) (NCT04431687)Chong Kun Dang Pharmaceutical2020-06-15
A Clinical Study to Evaluate the Efficacy and Safety of CKD-351 (NCT04448223)Chong Kun Dang Pharmaceutical2020-06-11
The Purpose of Study is to Evaluate the Safety, Pharmacokinetics and Anti-tumor Effects of CKD-702 in Patients With Advanced or Metastatic Non-small Cell Lung Cancer Who Failed to Standard Therapy (NCT04667975)Chong Kun Dang Pharmaceutical2020-05-21
Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-393 in Healthy Subjects (NCT04260438)Chong Kun Dang Pharmaceutical2020-04-08
Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-389 (NCT04322032)Chong Kun Dang Pharmaceutical2020-04-06
A Clinical Trial to Compare the Pharmacokinetics and Tolerability of CKD-348 (NCT04258865)Chong Kun Dang Pharmaceutical2020-03-25
A Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-396 (NCT04246190)Chong Kun Dang Pharmaceutical2020-02-24
A Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-386 in Healthy Adult Volunteers (NCT04223895)Chong Kun Dang Pharmaceutical2020-02-01
A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-375 (NCT04221360)Chong Kun Dang Pharmaceutical2020-01-29
Evaluation of the Safety and Tolerability of CKD-510 in Healthy Subjects (NCT04746287)Chong Kun Dang Pharmaceutical2020-01-14
A Clinical Trial to Evaluate the Efficacy and Safety of CKD-495 (NCT04255589)Chong Kun Dang Pharmaceutical2020-01-06
Compare the Pharmacokinetics and Safety of CKD-391 (NCT04354987)Chong Kun Dang Pharmaceutical2019-10-30
Clinical Study to Evaluate the Efficacy and Safety of CKD-348(CKD-828, D326, D337) Tablet (NCT04388215)Chong Kun Dang Pharmaceutical2019-10-23
Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-385 in Healthy Volunteers (NCT04075643)Chong Kun Dang Pharmaceutical2019-09-19
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting) (NCT04083872)Chong Kun Dang Pharmaceutical2019-09-06
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed) (NCT04083846)Chong Kun Dang Pharmaceutical2019-09-06
Clinical Trial to Evaluate the Efficacy and Safety of CKD-386 (NCT04312698)Chong Kun Dang Pharmaceutical2019-08-29
Pharmacokinetics, Safety and Tolerability of CKD-387 10/500mg BE Phase1 (NCT04156685)Chong Kun Dang Pharmaceutical2019-08-06
A Clinical Study to Compare the Safety and Pharmacokinetics of CKD-320 and D012 (NCT04035538)Chong Kun Dang Pharmaceutical2019-08-01
Efficacy and Safety of Once-Daily Tacrolimus in Liver Transplant Recipients (SOUL) (NCT04069065)Chong Kun Dang Pharmaceutical2019-07-31
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of CKD-333 in Healthy Volunteers (NCT04019743)Chong Kun Dang Pharmaceutical2019-07-28
Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-348 in Healthy Volunteers (NCT04272502)Chong Kun Dang Pharmaceutical2019-06-04
A Clinical Trial to Evaluate the Efficacy and Safety of CKD-825 in Patients With Atrial Fibrillation (NCT03950843)Chong Kun Dang Pharmaceutical2019-04-23
The Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-375 (NCT03848637)Chong Kun Dang Pharmaceutical2019-04-14
A Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-386 in Healthy Male Volunteers (NCT03920579)Chong Kun Dang Pharmaceutical2019-04-01
Study to Evaluate the Bioequivalence of Astellas Phama Korea Inc. "Harnal-D" in Healthy Volunteers (NCT03887858)Chong Kun Dang Pharmaceutical2019-03-11
Study to Evaluate the Bioequivalence of Astellas Phama Korea Inc. "Harnal-D" in Healthy Volunteers After Meal (NCT03887871)Chong Kun Dang Pharmaceutical2019-03-11
Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-374 5 mg in Healthy Volunteers (NCT03858725)Chong Kun Dang Pharmaceutical2019-02-26
Compare the Pharmacokinetics and Safety of CKD-333 With Co-administration CKD-330 and D090 in Healthy Male Adults (NCT03849287)Chong Kun Dang Pharmaceutical2019-02-25
Study to Evaluate the Bioequivalence of Pfizer Korea Inc. "XELJANZ 5Mg Tablet" in Healthy Volunteers (NCT03868072)Chong Kun Dang Pharmaceutical2019-02-22
Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-370 and D745 in Healthy Adults (NCT03849495)Chong Kun Dang Pharmaceutical2019-02-19
A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-355 (NCT03802162)Chong Kun Dang Pharmaceutical2019-02-15
Clinical Trial to Evaluate the Efficacy and Safety of EsoDuo Tab. 20/800mg (NCT03928470)Chong Kun Dang Pharmaceutical2019-01-29
Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D635 Under Fed Condition (NCT03849339)Chong Kun Dang Pharmaceutical2019-01-28
Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D635 in Healthy Adults (NCT03849261)Chong Kun Dang Pharmaceutical2019-01-14
The Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-387 Under Fed Condition (NCT03738449)Chong Kun Dang Pharmaceutical2019-01-08
Retrospective Study to Evaluate the Safety of Duvie in Korean Patients With Type 2 Diabetes Mellitus (NCT05043467)Chong Kun Dang Pharmaceutical2019-01-02
Study to Evaluate the Efficacy and Safety of Tacrolimus in Kidney Transplant Recipients (BLOSSOM) (NCT04224350)Chong Kun Dang Pharmaceutical2018-12-17
A Clinical Study to Evaluate the Efficacy and Safety of CKD-351 (NCT03762369)Chong Kun Dang Pharmaceutical2018-12-07
A Study Evaluating the Efficacy and Safety of CKD-506 in Adult Subjects With Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response to Methotrexate (NCT04204603)Chong Kun Dang Pharmaceutical2018-11-30
Clinical Trial to Evaluate Pharmacokinetic Profiles and Safety Between CKD-385 and D935 in Healthy Volunteers (NCT03748212)Chong Kun Dang Pharmaceutical2018-10-24
A Study To Evaluate CKD-701 and Lucentis® in Patients With Neovascular(Wet) Age Related Macular Degeneration (NCT04857177)Chong Kun Dang Pharmaceutical2018-10-19
Clinical Trial to Evaluate the Efficacy and Safety of TenofoBell® Tablet in Chronic Hepatitis B Patients (NCT04539652)Chong Kun Dang Pharmaceutical2018-09-20
Compare the Pharmacokinetics and Safety of CKD-391 With Co-administration of D086 and D337 (NCT03793985)Chong Kun Dang Pharmaceutical2018-09-05
Study to Evaluate the Efficacy and Safety of Once-Daily Tacrolimus in Kidney Transplant Recipients (NCT03749356)Chong Kun Dang Pharmaceutical2018-09-05
A Study to Investigate Drug-Drug Interaction Between D326, D337 and CKD-828 in Healthy Subjects (NCT03726866)Chong Kun Dang Pharmaceutical2018-08-31
Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D484 in Healthy Adults (NCT03646799)Chong Kun Dang Pharmaceutical2018-08-30
A Study to Investigate Drug Interaction Between D326, D337, and D013 in Healthy Male Subjects (NCT03609606)Chong Kun Dang Pharmaceutical2018-08-09
Pharmacokinetics and Safety Profile of CKD-333 (NCT03659149)Chong Kun Dang Pharmaceutical2018-08-08
Clinical Trial to Evaluate the Drug Drug Interaction of CKD-501 and D308 (NCT03616392)Chong Kun Dang Pharmaceutical2018-07-25
Clinical Study to Compare the Pharmacokinetic Characteristics and Safety Between CKD-380 10mg and D308 10mg (NCT03601910)Chong Kun Dang Pharmaceutical2018-07-16
The Clinical Trial to Evaluate the Efficacy and Safety of CKD-497 (NCT03726853)Chong Kun Dang Pharmaceutical2018-05-29
Clinical Study to Compare the Pharmacokinetic Characteristics and Safety Between CKD-357 and D578 in Healthy Volunteers (NCT03671941)Chong Kun Dang Pharmaceutical2018-05-25
CKD-504 in SAD and MAD in Healthy Korean and Caucasian Adult Male and Female Subjects (NCT03713892)Chong Kun Dang Pharmaceutical2018-05-23
The Efficacy and Safety of CKD-501 Added to D150 Plus D759 Therapy in Patients With Type 2 Diabetes (NCT03641352)Chong Kun Dang Pharmaceutical2018-05-02
CKD-355 Drug-drug Interaction Study (CKD-355 DDI P1) (NCT03569579)Chong Kun Dang Pharmaceutical2018-04-16
Clinical Trial to Evaluate the Efficacy and Safety of CKD-333 Tablet (NCT03583905)Chong Kun Dang Pharmaceutical2018-04-04
Impact of Lymphocyte Anti-metabolite Immunosuppressions on Donor-Specific Anti-HLA Antibody and Kidney Graft Outcome (NCT03794492)Chong Kun Dang Pharmaceutical2018-03-31
A Study to Compare PK and Safety of CKD-381 and D026 in Healthy Male Subjects (NCT03444402)Chong Kun Dang Pharmaceutical2018-03-02
Clinical Trial to Evaluate the Efficacy and Safety of CKD-495 Tablet (NCT03437785)Chong Kun Dang Pharmaceutical2018-01-16
Retrospective Observational Study on GERD Management in General Hospitals in Korea (NCT06974903)Chong Kun Dang Pharmaceutical2018-01-03
Study to Evaluate the Pharmacokinetics and Tolerability of Tacrolimus in Kidney Transplant Recipients. (NCT04102943)Chong Kun Dang Pharmaceutical2017-11-30
Efficacy and Safety of CKD-501 Added to D150 Plus D745 10mg Therapy in Patients With Type 2 Diabetes (NCT03739125)Chong Kun Dang Pharmaceutical2017-11-07
A Clinical Trial to Assess the Effects of Food on the Bioavailability of CKD-337 (NCT03382756)Chong Kun Dang Pharmaceutical2017-10-12
Clinical Trial to to Compare of the Efficacy and Safety of Lipilou® 20 mg and Lipilou® 10 mg (NCT04511000)Chong Kun Dang Pharmaceutical2017-10-11
A Clinical Trial to Evaluate the Blood Pressure Lowering Effect of a Candemore Plus Tab Versus Cantabell Tab in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy (NCT04521023)Chong Kun Dang Pharmaceutical2017-09-20
← Previous Next →

Track Chong Kun Dang Pharmaceutical automatically

Every clearance here is in the API, with alerts when new ones post.